Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02431143
Other study ID # LEAP 0714
Secondary ID
Status Completed
Phase Phase 2
First received April 20, 2015
Last updated October 10, 2016
Start date May 2015
Est. completion date September 2016

Study information

Verified date October 2016
Source Drugs for Neglected Diseases
Contact n/a
Is FDA regulated No
Health authority Kenya: Pharmacy and Poisons Board
Study type Interventional

Clinical Trial Summary

This is a multicenter, non-comparative, open-label clinical trial to assess the Pharmacokinetics (PK) and safety of miltefosine using an allometric dose algorithm in the treatment of children with primary Visceral Leishmaniasis (VL) in eastern Africa. Efficacy and Pharmacodynamics (PD) will be assessed as secondary outcomes.

The proposed study aims to assess whether drug exposure in children can be increased to equivalent adult drug exposure by using the miltefosine allometric dose given BID for 28 days in paediatric VL patients aged 4-12y and whether this dose is tolerable. The present study is also expected to provide the basis for minimum time to reach sufficient drug exposure for miltefosine activity to guide optimal treatment duration to be used in combination therapy for visceral leishmaniasis. The PK data will be assessed in this trial using a compartmental population PK approach.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date September 2016
Est. primary completion date April 2016
Accepts healthy volunteers No
Gender Both
Age group 4 Years to 12 Years
Eligibility Inclusion Criteria:

- Patients with clinical signs and symptoms of VL and confirmatory parasitological microscopic diagnosis

- Patients aged > 4 to < 12 years who are able to comply with the study protocol.

- Patients for whom written informed consent has been signed by parents(s) or legal guardian

- Weight < 30 kg

Exclusion Criteria:

- Patients who are relapse cases

- Patients who have received any anti-leishmanial drugs in the last 6 months

- Patients with severe malnutrition (for children aged <5 years, weight-for-height WHO reference curves by gender, z score <-3; for children 5-12 years, BMI-for-age WHO reference curves for gender, z score < -3)

- Patients with positive HIV diagnosis

- Patients with previous history of hypersensitivity reaction to miltefosine

- Patients suffering from a concomitant severe infection such as Tuberculosis (TB) or any other serious underlying disease (cardiac, renal, hepatic) which would preclude evaluation of the patient's response to study medication

- Patients suffering from other conditions associated with splenomegaly such as schistosomiasis

- Pregnant or lactating women or female patient in childbearing age (reached menarche)

- Patients with haemoglobin < 5g/dl

- Patients with White Blood Cells (WBC) < 1 x 10³/mm³

- Patients with platelets < 40,000/mm³

- Patients with abnormal liver function (ALT and AST) tests of more than three times the normal range.

- Patients with bilirubin more than 1.5 times the upper normal range

- Patients with serum creatinine above the upper limit of normal (ULN) for age and gender.

- Patients with clinical signs of severe VL disease such as jaundice and bleeding

- Patients who cannot comply with the planned scheduled visits and procedures of the study protocol

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Miltefosine


Locations

Country Name City State
Kenya Kacheliba Hospital Kacheliba Rift Valley, West Pokot
Uganda Amudat Hospital Amudat Karamoja

Sponsors (1)

Lead Sponsor Collaborator
Drugs for Neglected Diseases

Countries where clinical trial is conducted

Kenya,  Uganda, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetics Parameters (Area Under the Curve (AUC) - composite outcome) Area Under the Curve calculation is based on several timepoints from first drug intake up to complete elimination of the drug. During treatment, at 1 and 6 months follow-up No
Primary Safety (composite outcome) adverse events 1. Frequency of Serious Adverse Events (SAEs) and Adverse Events (AEs) requiring treatment discontinuation, 2. Frequency and severity of adverse events until day 210 Yes
Primary Pharmacokinetics Parameters (Css/Cmax) Day 28 No
See also
  Status Clinical Trial Phase
Terminated NCT02839603 - Asymptomatic Leishmania Infection in HIV Patients
Completed NCT00370825 - Combination Chemotherapy for the Treatment of Indian Kala-Azar Phase 2
Recruiting NCT05426577 - Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure
Completed NCT01069198 - A Community Trial for Visceral Leishmaniasis (VL) N/A
Completed NCT00371995 - Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar Phase 2
Completed NCT00604955 - Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Phase 4
Completed NCT01032187 - Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Phase 4
Completed NCT00342823 - Immunogenetics of Visceral Leishmaniasis N/A
Completed NCT04003532 - LAMP Assay for the Diagnosis of Visceral Leishmaniasis
Terminated NCT01980199 - Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan Phase 2
Completed NCT00255567 - Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Phase 3
Not yet recruiting NCT06118749 - Leishmania Antigen Rapid Diagnostic Test Proof-of-Concept and Validation Study
Recruiting NCT04342715 - A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
Completed NCT01122771 - Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Phase 3
Completed NCT03636659 - Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition Phase 1
Not yet recruiting NCT01566552 - Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Phase 4
Completed NCT00696969 - Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Phase 3
Completed NCT00318721 - Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar N/A
Completed NCT00216346 - Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Phase 3
Completed NCT02011958 - Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Phase 3